Associated tags: SAN, Pharmaceutical industry, Decentralized Trials & Research Alliance, DTRA, Research, Clinical trial, DCTS, Entrepreneurship, Patient, DCT, Education, Annual general meeting, EMA, Risk management, FDA
Retrieved on:
Wednesday, November 8, 2023
SCRS,
FDA,
DCT,
Biomedical Advanced Research and Development Authority,
Office of the National Coordinator for Health Information Technology,
National Institutes of Health,
Face,
European Medicines Agency,
Organization,
BARDA,
Entrepreneurship,
Research,
Development,
DTRA,
DCTS,
Clinical trial,
Decentralized Trials & Research Alliance,
EMA,
Annual general meeting,
NIH,
Government agency,
ONC,
Chairperson,
Map,
Government,
SAN,
Pharmaceutical industry,
Medical device SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- The Decentralized Trials & Research Alliance (DTRA), a global alliance focused on the adoption of decentralized trials, today concluded its 2023 Annual Meeting, including members from biopharmaceutical companies, government agencies, research sites, healthcare organizations, patient groups, and service and technology companies.
Key Points:
- SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- The Decentralized Trials & Research Alliance (DTRA), a global alliance focused on the adoption of decentralized trials, today concluded its 2023 Annual Meeting, including members from biopharmaceutical companies, government agencies, research sites, healthcare organizations, patient groups, and service and technology companies.
- The DTRA community learned of their strategic intentions regarding decentralized clinical trial (DCT) adoption, drivers to achieve scale with these methods, and the importance of DCT to our research ecosystem.
- DTRA has harnessed this industry-leading expertise into creating new resources, sharing key learnings, and establishing best practices for research teams to use in implementing DCTs.
- “Each of our Initiative outputs is available at www.dtra.org and the resources are available to all.”
Customer success,
Clinical trial,
Decentralized Trials & Research Alliance,
Research,
DCTS,
DTRA,
Patient engagement in Canada,
Thought,
Medidata Solutions,
Patient,
SAN,
Vaccine,
Team,
Pharmaceutical industry,
Nursing,
Medical imaging SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) -- The Decentralized Trials & Research Alliance (DTRA) today has announced the release of Patient Journey Maps to help researchers understand participation considerations and burden and to maximize patient inclusion, diversity, and participation in research.
Key Points:
- SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) -- The Decentralized Trials & Research Alliance (DTRA) today has announced the release of Patient Journey Maps to help researchers understand participation considerations and burden and to maximize patient inclusion, diversity, and participation in research.
- “The patient journey maps can be used as guidelines for others in the industry to find ways to truly embrace the patient perspective when it comes to decentralized clinical trials,” said Alicia Staley, Vice President of Patient Engagement at Medidata and Co-Lead of the DTRA Patient Journey Map initiative.
- Our team delivered a unique set of patient journey maps across three different therapeutic areas, which will enhance access and engagement in clinical trials.”
By visualizing the decision points that patients face in their treatment and clinical research experience, study teams can fully appreciate and anticipate the patient journey.
- “We have successfully identified the patient journey for incorporating Decentralized Clinical Trials (DCTs) in clinical trials.
Retrieved on:
Friday, February 24, 2023
Clinical trial,
Ecosystem,
Regulation,
Drug development,
Decentralized Trials & Research Alliance,
Patient,
DCT,
SAN,
DTRA,
Operational definition,
Patient experience,
Pharmaceutical industry,
Risk management,
Success,
Rubric SAN DIEGO, Feb. 24, 2023 (GLOBE NEWSWIRE) -- The Decentralized Trials & Research Alliance (DTRA), today announced the release of the Best Practices Rubric to aid stakeholders in evaluating decentralized clinical trial (DCT) best practices across the span of the trial lifecycle, from program planning to trial close and analysis.
Key Points:
- SAN DIEGO, Feb. 24, 2023 (GLOBE NEWSWIRE) -- The Decentralized Trials & Research Alliance (DTRA), today announced the release of the Best Practices Rubric to aid stakeholders in evaluating decentralized clinical trial (DCT) best practices across the span of the trial lifecycle, from program planning to trial close and analysis.
- This Rubric solves the problem: How would you assess whether a process is a DCT best practice?
- The Rubric provides a consistent framework by which DCT practices may be evaluated.
- Mike DeMarco shared “The DTRA Best Practices Rubric provides a consistent framework by which DCT practices may be evaluated.
Retrieved on:
Thursday, November 10, 2022
SAN,
GLOBE,
Priority,
Data collection,
DTRA,
DCTS,
Mission,
CVS,
Annual,
Method,
DCT,
Data technology,
Danish Medicines Agency,
Annual general meeting,
Ministry,
Proceedings of the Human Factors and Ergonomics Society Annual Meeting,
Research,
Education,
Adoption,
Ministry of Health (Israel),
BMS,
Evidence,
Alaska Federal Health Care Access Network,
Cros,
EMA,
Publication,
Entrepreneurship,
Decentralized Trials & Research Alliance,
Sanofi,
Industry,
FDA,
Pharmaceutical industry,
Renewable energy,
Risk management,
Parexel SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- The Decentralized Trials & Research Alliance (DTRA), a non-profit organization dedicated to the global adoption of decentralized clinical trials and research within life sciences and healthcare, today announced several key initiative updates that will continue to progress throughout 2023. Specialized DTRA teams presented these initiatives during its 2nd Annual Meeting in Boston, MA, from November 6-9, 2022. The meeting was attended by select professionals from its global membership of leaders in decentralized clinical trials (DCTs) including regulators, pharmaceutical and biotechnology sponsors, contract research organizations (CROs) and other service providers, technology companies, research sites, and advocacy leaders.
Key Points:
- SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- The Decentralized Trials & Research Alliance (DTRA), a non-profit organization dedicated to the global adoption of decentralized clinical trials and research within life sciences and healthcare, today announced several key initiative updates that will continue to progress throughout 2023.
- Specialized DTRA teams presented these initiatives during its 2nd Annual Meeting in Boston, MA, from November 6-9, 2022.
- The Decentralized Trials & Research Alliance ( DTRA ), a non-profit organization, was convened to enable collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research.
- It works to make research participation accessible to everyone, enabled by the consistent, widespread adoption of appropriate decentralized research methods.
Program,
Research,
SAN,
Tower of Babel,
Entrepreneurship,
Solution,
Â,
LinkedIn,
Education,
Organization,
GLOBE,
Decentralized Trials & Research Alliance,
DTRA,
Twitter,
Terminology,
Adoption,
Patient,
Cryptocurrency,
Pharmaceutical industry SAN DIEGO, Aug. 29, 2022 (GLOBE NEWSWIRE) -- The Decentralized Trials & Research Alliance (DTRA) today has announced the release of the DTRA Glossary, a result of cross-industry collaboration meant to improve the global adoption of decentralized research.
Key Points:
- SAN DIEGO, Aug. 29, 2022 (GLOBE NEWSWIRE) -- The Decentralized Trials & Research Alliance (DTRA) today has announced the release of the DTRA Glossary, a result of cross-industry collaboration meant to improve the global adoption of decentralized research.
- The DTRA Glossary is the first output from DTRAs 12 initiatives spanning four priorities as developed by the DTRA Leadership Council.
- The Decentralized Trials & Research Alliance ( DTRA ), a non-profit organization, was convened to enable collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research.
- It works to make research participation accessible to everyone, enabled by the consistent, widespread adoption of appropriate decentralized research methods.
b'SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- The Decentralized Trials & Research Alliance ( DTRA ) today announced priorities and initial initiatives designed to realize the full potential of decentralized research to improve access and participation to make clinical trials more efficient, accessible, and equitable.
Key Points:
- b'SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- The Decentralized Trials & Research Alliance ( DTRA ) today announced priorities and initial initiatives designed to realize the full potential of decentralized research to improve access and participation to make clinical trials more efficient, accessible, and equitable.
- With more than 100 Member Organizations, DTRA is the leading multi-stakeholder initiative focused on accelerating the global adoption of decentralized research.\nDTRA members have defined four priority areas as a framework for new initiatives:\nTo establish common nomenclature & definitions, archetypes and key performance indicators around the practice of decentralized research.\nTo identify and promote best practices in decentralized research.\nTo prioritize education by building a knowledge repository and mechanisms for information sharing.\nTo identify and remove barriers to decentralized research implementation, establishing roadmaps to their resolution.\nA full listing of the initiatives grouped by priority area is available here .
- Members include life-sciences research companies and patient advocacy organizations; technology and service providers; and leading regulatory authorities, such as the U.S. Food and Drug Administration.\nThe Decentralized Trials & Research Alliance ( DTRA ) was convened to enable collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research.
- It works to make research participation accessible to everyone, enabled by the consistent, widespread adoption of appropriate decentralized research methods.\nFor further information please contact:\n'
b'SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- The Decentralized Trials & Research Alliance (DTRA) today announced that it now counts more than 100 member organizations united in the shared mission to make clinical-trial participation widely accessible to patients.
Key Points:
- b'SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- The Decentralized Trials & Research Alliance (DTRA) today announced that it now counts more than 100 member organizations united in the shared mission to make clinical-trial participation widely accessible to patients.
- DTRA is the largest and only multi-stakeholder initiative focused on the global adoption of decentralized research methodology.\nRanging from life-sciences research companies to patient advocacy organizations, technology and service providers, and leading regulatory authorities, such as the U.S. Food and Drug Administration, the 100+ DTRA members are engaged in advancing policies, research practices and technologies that will accelerate the global adoption of patient-focused, inclusive, decentralized clinical trials and research.\n\xe2\x80\x9cThe commitment of these organizations and their reach and scale underscore our collective potential for advancing decentralized research,\xe2\x80\x9d said Amir Kalali, MD, co-chair of DTRA, life sciences executive, and founder of several collaborative life science communities.\n\xe2\x80\x9cWhile the COVID-19 pandemic accelerated the adoption of decentralized research, we are now seeing the commitment of the research community working together to become a core resource in the clinical research toolkit,\xe2\x80\x9d said Craig Lipset, DTRA co-chair, clinical innovation advisor, and a pioneer in decentralized trials.
- \xe2\x80\x9cWe are proud that the DTRA can serve as the center for the future of decentralized research.\xe2\x80\x9d\nFor a listing of the organizations participating in DTRA or for those interested in being part of the alliance, visit DTRA.org .\nThe Decentralized Trials & Research Alliance ( DTRA ) was convened to enable collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research.
- It works to make research participation accessible to everyone, enabled by the consistent, widespread adoption of appropriate decentralized research methods.\nFor further information please contact:\n'
Retrieved on:
Thursday, December 10, 2020
SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- A historic alliance of life sciences and healthcare organizations seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research.
Key Points:
- SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- A historic alliance of life sciences and healthcare organizations seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research.
- The Decentralized Trials & Research Alliance (DTRA) plans to unite stakeholders, including healthcare companies, regulators, patient groups and research organizations, with a mission to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research.
- The COVID-19 pandemic has forced organizations to adopt decentralized methodologies which have the potential to broadly accelerate drug development.
- Organizations interested in taking part can visit DTRA.org
The Decentralized Trials & Research Alliance ( DTRA ) was convened to enable collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research.
